and our to and Welcome with Allison, therapy you, our our I'll selected everyone. of morning, highlights Sanofi corporate evolution, elements good restructuring gene earnings portfolio recent discuss of Today, call. relationship Genzyme. the QX including Thank
And achieving focused steps remarks. the entered our with and take new prepared disease. our fully discovery Medical Khwaja, after second Q&A joined second Operating and will up wrap the Officer our of to XXXX strategic Next, Officer Allison with Ottmer, quarter, discussion for programs goal. has R&D, continued call of Mat the Head in will becoming on biopharmaceutical us focused in We quarter for on our neurological existing efforts. Omar therapy Chief severe Chief a comment our the company vision we integrated results. leading also a that AAV gene of
approaches. program pursue opportunities our under previously, As we've outlined will we new with distinct X plan,
when discovery an IND point, earlier typically a up responsibility. on and first partner, stage, is takes with The programs partner development commercial to full novel future the approach advance the to
up be milestones, operations. in into currently fund payments, with can and Both than Under payment of all We're development across AbbVie as upfront for resources, funneled funding development which near-term the support back rights. reimbursement our discovery payments typically approach. through an we million cost these more with to research over eligible Neurocrine the milestones provide but $XXX with partners approach, and candidates retain well this partners' as and later-stage and where activities second the eligible Our royalty programs milestone existing follow advance the for and co-development and of programs the coming programs. years preclinical co-commercialization programs
and Friedreich's approach. programs with with Parkinson's Our Neurocrine ataxia align this
an this in do for partners us way maintaining while meaningful more selected with participation. Working option to allows commercial
our indications. program in future to for of muscular simplify IP collaboration U.S. to the non-CNS use advance doing previously granting transaction, U.S. we and program the With the rights, was Finally value. this with ataxia eliminate program retain turn, key orphan In option of our were Neurocrine own exchange we greatly certain portfolio and relationship the therapy to restructuring disease that – development program. we atrophy the program. and certain rights to Genzyme's with the Sanofi the upside granting part Genzyme Sanofi third rights promising of of this And transferred of concerning terms in in in exclusive included on Friedreich's the program the capsids Sanofi agreement. X we ex of for with our program, rights ataxia the of the rights approach, able gain Part we spinal gene collaboration of Genzyme. full June, worldwide to ex the so, to our Huntington's the announced our to option the Friedreich's future In value the in to a execution
is was our no to we existing Gaining the U.S. restructuring. There got. rights cash global Huntington's in people affects Huntington's the motivation Doing the rights reduce to for our alone. around so treatment for disease, program which allowed in us XX,XXX outlay primary
results the studies. gene we by significantly in of we encouraged are and our expression of large of of past, deeper preclinical the in and putamen VY-HTTXX HTT we've We've can the thalamus that brain. in reduce presented As tissues animals, outer discussed the both through data demonstration layers showing
leverage those gained delivery is Our impact can we this we've meaningful our the Parkinson's disease. and a experience program, from by we make to believe affected
IND we working currently XXXX. end of is If be made, to IND-enabling file are We a may progress studies. an successful position by in on the
In restructured alter other work partner on and decided we Huntington's the and Sanofi our begun focus with In we've new to efforts deployment in to to engage our program discovery we programs, potential a in the connection advance to Genzyme the intend ALS, order discussions to with collaborators. of relationship, resources. with
taking we we're steps team. advance to and As are expertise to reshape on these our to build portfolio, strengthen continuing and management our our
pleased quarter, recently have to Omar's expanded us Roche Chief joining of most she is was Bales, past We're Head the at as was VP Kelly R&D. During of Senior Officer in Head Kelly we Global Discovery. recruited of role and Neuroscience and to where Medical September Neuroscience. very Research who also Head of
technologies to additional on academic efforts. expect corporate our our potential further solely targets, programs, relying additions expertise also come. our internal along help forward But with We look on partners efforts. the and updates efforts exciting in new capsid in our programs assess I to portfolio could may us result to near actively We're pipeline discovery that in future. on we're our discovery that engaged and to efforts months with not providing
With over that, Omar? call the I'll turn to Omar.